Cambridge Investment Research Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43.8M | Buy |
1,820,575
+28,558
| +2% | +$747K | 0.1% | 202 |
|
|
2026
Q1 | $50.3M | Sell |
1,792,017
-29,983
| -2% | -$798K | 0.13% | 148 |
|
|
2025
Q4 | $45.4M | Buy |
1,822,000
+9,313
| +0.5% | +$235K | 0.12% | 164 |
|
|
2025
Q3 | $46.2M | Sell |
1,812,687
-88,815
| -5% | -$2.19M | 0.13% | 145 |
|
|
2025
Q2 | $46.1M | Buy |
1,901,502
+121,272
| +7% | +$2.83M | 0.14% | 130 |
|
|
2025
Q1 | $45.1M | Buy |
1,780,230
+64,277
| +4% | +$1.68M | 0.15% | 127 |
|
|
2024
Q4 | $45.5M | Sell |
1,715,953
-31,803
| -2% | -$863K | 0.15% | 121 |
|
|
2024
Q3 | $50.6M | Sell |
1,747,756
-28,849
| -2% | -$842K | 0.17% | 108 |
|
|
2024
Q2 | $49.7M | Buy |
1,776,605
+75,444
| +4% | +$2.08M | 0.18% | 101 |
|
|
2024
Q1 | $47.2M | Buy |
1,701,161
+111,509
| +7% | +$3.09M | 0.18% | 99 |
|
|
2023
Q4 | $45.8M | Buy |
1,589,652
+136,467
| +9% | +$4.13M | 0.2% | 91 |
|
|
2023
Q3 | $48.2M | Sell |
1,453,185
-93,885
| -6% | -$3.32M | 0.23% | 83 |
|
|
2023
Q2 | $56.7M | Buy |
1,547,070
+225,184
| +17% | +$8.76M | 0.26% | 64 |
|
|
2023
Q1 | $53.9M | Sell |
1,321,886
-42,836
| -3% | -$1.85M | 0.26% | 65 |
|
|
2022
Q4 | $69.9M | Sell |
1,364,722
-2,157
| -0.2% | -$103K | 0.36% | 51 |
|
|
2022
Q3 | $59.8M | Sell |
1,366,879
-19,404
| -1% | -$943K | 0.34% | 54 |
|
|
2022
Q2 | $72.7M | Buy |
1,386,283
+7,162
| +0.5% | +$365K | 0.39% | 48 |
|
|
2022
Q1 | $71.4M | Sell |
1,379,121
-161,010
| -10% | -$8.35M | 0.33% | 55 |
|
|
2021
Q4 | $90.9M | Buy |
1,540,131
+76,914
| +5% | +$3.81M | 0.41% | 40 |
|
|
2021
Q3 | $62.9M | Sell |
1,463,217
-126,671
| -8% | -$5.61M | 0.31% | 56 |
|
|
2021
Q2 | $62.3M | Buy |
1,589,888
+105,200
| +7% | +$4.09M | 0.3% | 58 |
|
|
2021
Q1 | $53.8M | Sell |
1,484,688
-3,721
| -0.2% | -$132K | 0.29% | 61 |
|
|
2020
Q4 | $54.8M | Sell |
1,488,409
-40,126
| -3% | -$1.47M | 0.32% | 61 |
|
|
2020
Q3 | $53.2M | Buy |
1,528,535
+129,930
| +9% | +$4.56M | 0.36% | 52 |
|
|
2020
Q2 | $43.4M | Buy |
1,398,605
+19,606
| +1% | +$666K | 0.33% | 56 |
|
|
2020
Q1 | $42.7M | Buy |
1,378,999
+246,825
| +22% | +$8.41M | 0.41% | 46 |
|
|
2019
Q4 | $42.1M | Buy |
1,132,174
+69,567
| +7% | +$2.48M | 0.33% | 57 |
|
|
2019
Q3 | $36.2M | Buy |
1,062,607
+13,392
| +1% | +$487K | 0.32% | 62 |
|
|
2019
Q2 | $43.1M | Buy |
1,049,215
+64,299
| +7% | +$2.55M | 0.4% | 43 |
|
|
2019
Q1 | $39.7M | Sell |
984,916
-94,685
| -9% | -$3.79M | 0.38% | 41 |
|
|
2018
Q4 | $44.7M | Buy |
1,079,601
+95,322
| +10% | +$3.96M | 0.49% | 33 |
|
|
2018
Q3 | $41.2M | Buy |
984,279
+14,661
| +2% | +$564K | 0.39% | 39 |
|
|
2018
Q2 | $33.4M | Sell |
969,618
-25,801
| -3% | -$882K | 0.35% | 48 |
|
|
2018
Q1 | $33.5M | Buy |
995,419
+123,969
| +14% | +$4.26M | 0.38% | 42 |
|
|
2017
Q4 | $29.9M | Buy |
871,450
+11,455
| +1% | +$391K | 0.35% | 47 |
|
|
2017
Q3 | $29.1M | Buy |
859,995
+13,316
| +2% | +$428K | 0.39% | 43 |
|
|
2017
Q2 | $27M | Buy |
846,679
+12,587
| +2% | +$397K | 0.4% | 42 |
|
|
2017
Q1 | $27.1M | Buy |
834,092
+52,533
| +7% | +$1.66M | 0.46% | 39 |
|
|
2016
Q4 | $24.1M | Buy |
781,559
+8,514
| +1% | +$260K | 0.45% | 42 |
|
|
2016
Q3 | $24.8M | Buy |
773,045
+47,662
| +7% | +$1.59M | 0.46% | 43 |
|
|
2016
Q2 | $24.2M | Buy |
725,383
+60,141
| +9% | +$1.92M | 0.51% | 40 |
|
|
2016
Q1 | $18.7M | Buy |
665,242
+35,710
| +6% | +$1.02M | 0.42% | 50 |
|
|
2015
Q4 | $19.3M | Buy |
629,532
+16,688
| +3% | +$525K | 0.46% | 42 |
|
|
2015
Q3 | $18.3M | Buy |
612,844
+4,311
| +0.7% | +$138K | 0.52% | 36 |
|
|
2015
Q2 | $19.4M | Buy |
608,533
+63,874
| +12% | +$2.08M | 0.54% | 35 |
|
|
2015
Q1 | $18M | Buy |
544,659
+10,995
| +2% | +$350K | 0.51% | 40 |
|
|
2014
Q4 | $15.8M | Sell |
533,664
-23,220
| -4% | -$666K | 0.49% | 44 |
|
|
2014
Q3 | $15.6M | Buy |
556,884
+27,119
| +5% | +$761K | 0.46% | 44 |
|
|
2014
Q2 | $14.9M | Buy |
529,765
+85,540
| +19% | +$2.44M | 0.52% | 40 |
|
|
2014
Q1 | $13.5M | Buy |
444,225
+7,640
| +2% | +$228K | 0.51% | 41 |
|
|
2013
Q4 | $12.7M | Buy |
436,585
+38,273
| +10% | +$1.11M | 0.52% | 38 |
|
|
2013
Q3 | $10.9M | Sell |
398,312
-38,456
| -9% | -$1.05M | 0.48% | 44 |
|
|
2013
Q2 | $11.6M | Buy |
+436,768
| New | +$12.1M | 0.59% | 33 |
|
Other funds holding PFE
Cambridge Investment Research Advisors's PFE Position: Q2 2026 in Review
Cambridge Investment Research Advisors increased its Pfizer (PFE) stake by 1.6% in Q2 2026, buying an estimated $747K and bringing the position to 1,820,575 shares worth $43.8M. The position accounts for 0.1% of the portfolio, ranked #202.
Cambridge Investment Research Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $90.9M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Cambridge Investment Research Advisors held 1,820,575 shares of Pfizer worth $43.8M as of Q2 2026.
- Cambridge Investment Research Advisors bought 28,558 Pfizer shares in Q2 2026, an estimated $747K.
- Pfizer made up 0.1% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #202 holding.
- Cambridge Investment Research Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
- Cambridge Investment Research Advisors's Pfizer position peaked at $90.9M in Q4 2021.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.